Pharmacology
Aceclidine is 3-acetoxyquinuclidine (cf. molecular structure. Figure) . It is available as: (i) The salicylate (molecular weight 308 34, a 2 per cent. concentration corresponding to an o o65 molar solution). This is the preparation used by Lieberman and Leopold (1967) . A 2 per cent. solution of aceclidine salicylate is only o079 times as concentrated a molar solution as 2 per cent. pilocarpine nitrate.
(ii) Aceclidine hydrochloride (Glaucostat) with a molecular weight of 205 5. A 2 per cent. solution of the hydrochloride corresponds to an o-097 molar solution. It is interesting that pilocarpine HCI has a molecular weight of 244 7 I, a 2 per cent. solution corresponding to an 0o82 molar solution, i.e. intermediate between the two forms of aceclidine (Table I) . Aceclidine has a potent parasympathomimetic action in man and experimental animals and a very weak anticholinesterase activity. This action is accordingly abolished or greatly weakened by atropine but almost unaffected by cholinesterase (Mashkovski and Zaitzeva, I 960). In experimental animals it possesses a parasympathomimetic action superior to that of a similar dose of pilocarpine. It is less toxic than pilocarpine, the L.D.5o being o'ii6 g./kg. (in mouse intraperitoneally) and 0I05 g./kg. (in rat)-approximately twice that of pilocarpine. No tachyphylaxis has been noted after repeated doses in contrast to that seen with pilocarpine (Yankelowitz, I965) .
It is prepared in a lyophilized form and is mixed at the time of dispensing. In powder form it undergoes only a 5 per cent. loss of activity after 3 months at 370C. (Yankelowitz, I965) . The drug penetrates rapidly into the anterior chamber (Rouher, I966). hJon H. Romano
Description of the trial
The object of the trial was a direct comparison of the effect on the same eyes and under identical conditions of gutt. pilocarpine 2 per cent. and gutt. aceclidine HCI 2 per cent., both used three times a day. One eye received pilocarpine and the other aceclidine. The eyes were examined at the end of one week of therapy, and after a fixed interval, ij hours, from the last instillation. The following conditions were thought to be desirable: (a) Double-blind conditions to ensure lack of bias on the part of the patient in describing the symptoms, and greater objectivity on the part of the observer. (b) Use of a placebo for one week to each eye to eliminate the effect of previous medication; it is claimed that 32 hours are sufficient for this purpose (Agugini and Stecchi, I968) . (c) Cross-over after a further week of placebo.
MATERIAL AND METHODS
The trial covered a total of 54 eyes (27 cases). All were established cases of open-angle (chronic simple) glaucoma undergoing nmedical treatment (with pilocarpine: 36 eyes; pilocarpine and eserine: 3 eyes; pilocarpine and neutral adrenaline: I6 eyes; phospholine iodide and neutral adrenaline: i eye; adrenaline alone: 2 eyes).
SUITABILITY OF CASES
(I) No patient undergoing therapy with a carbonic anhydirase inhibitor and only one eye previously on a powerful anticholinesterase drug was included in the test. (In two eyes neutral adrenaline was continued during the trial.) (2) Visual acuity had to be at least i/6o in each eye to allow tonography to be performed in both eyes.
(3) Patients fulfilling the above requirements were considered suitable for the "full trial" (see later)
only if their anterior chamber depth and configuration were such that angle closure was considered unlikely to occur when miotic therapy was interrupted for a week. Patients with a previouslyrecorded high level of intraocular pressure (greater than 28-30 mm. Hg) were also considered unsuitable for the full trial.
In Groups 2 and 3, the non-placebo or shorter trial was carried out.
A. Fuli Trial (34 eyes) ( 100 Po = pressure after placebo Co = outflow after placebo Po/Co = Po/C after placebo P pilo = pressure after pilocarpine C pilo = outflow after pilocarpine Po/C pilo = Po/C after pilocarpine P acec = pressure after aceclidine C acec = outflow after aceclidine Po/C acec = Po/C after aceclidine browache, smarting, red eye, watering eye, running nostrils, watering mouth, blurring and/or darkening of vision, sneezing, gastrointestinal symptoms (cramps, diarrhoea).
(b) Observation of relative hyperaemia of two eyes.
(c) Estimation of pupil size either by using the graticule on Goldmann's perimeter, or by direct confrontation with the pupillometry wheel on the Hamblin/Morton ophthalmoscope under uniform conditions of lighting and fixing distant object. With practice, accuracy of o 25 mm. is possible (e.g. between the 2 5 and 3-0 mm. marks), considered adequate for the purposes of the test. (d) Applanation tonometry: using Goldmann tonometer mounted on Haag-Streit goo slit lamp, checked for accuracy before each session with calibration device for 20 and 6o mm. Hg. Three readings made on each eye, changing eyes between each reading, and mean pressure recorded.
(e) Tonography: using Schwarzer recording tonometer. P. taken as applanation reading. As far as possible 45 to 6o minutes allowed to elapse between recording of two eyes. Only good tracings accepted. Correction for scleral rigidity not included. (f) Pilocarpine 2 per cent. and aceclidine 2 per cent. dispensed at Hospital Pharmacy in bottles marked Right and Left plus a code symbol corresponding to a number in a scientifically randomized series.
(3) Third visit (end of second week). Questionnaire, etc., as on second visit.
Two sets of drops issued; (a) Two bottles of placebo for third week; (b) Two bottles of pilocarpine/aceclidine in sealed envelope for use at beginning of week four (date specified on envelope).
(4) Fourth visit (I4 days after third visit). Procedure as at third visit.
At the conclusion of the trial each patient resumed his previous therapy.
B. Non-placebo or "Short" Trial (20 eyes) (Table IIB) Table IIB Clinical particulars of I0 non-placebo cases (20 eyes) group.bmj.com on July 3, 2017 -Published by http://bjo.bmj.com/ Downloaded from One eye placed on gutt. pilocarpine 2 per cent. and the other on gutt. aceclidine 2 per cent. (according to the randomized series) for a period of 2 weeks. After 2 weeks, cross-over carried out.
Trial lasted 4 weeks as for standard trial, but included only three visits, I4 days apart, at which the procedure was the same as for the standard trial.
Results
The results were evaluated statistically, using Student's t-test. The t and P values are given in Table III . In the present study, aceclidine was found to have a definite effect in lowering the intraocular pressure of eyes with open-angle glaucoma. This is in agreement with all the published work. The overall mean pressure in cases on aceclidine was 1.53 mm. Hg higher than that in cases on pilocarpine 2 per cent., a difference that is not statistically significant. The difference between the mean pressure produced by the two drugs was higher in the non-placebo cases (I 72 mm.) than in the full trial cases (I '36 mm.), suggesting that in patients with a high initial intraocular pressure (or a shallow anterior chamber) a stronger concentration of aceclidine might be necessary.
These results are similar to the results of the chronic experiments of Demailly ( I968), in which the pressure in cases on pilocarpine was I 9' I mm. Hg, and that in cases on aceclidine 5I6 was 202 mm. Hg. However, in his acute experiments, pilocarpine produced a percentage fall in pressure of 27 (± 12) compared to 30o6 (± 13.8) for aceclidine. Leopold (1968) found, in acute experiments in cases of chronic simple glaucoma, that 2 per cent. aceclidine salicylate had a greater action in lowering the intraocular pressure than pilocarpine 2 per cent. Ittienne, Barut, and Gonzales-Bouchon (I967), in twenty cases of chronic simple glaucoma, found a mean lowering of the intraocular pressure with aceclidine of 7 65 mm. Hg. Agugini and Stecchi (I968) reported no difference in the hypotensive action of the two drugs when the three daily readings over 3 days were averaged, although the figure for aceclidine (2o095 mm. Hg) was slightly lower than that for pilocarpine (22 29 mm. Hg). Brancato and Boschi (i968) , comparing the action of the two drugs in ten subjects, found that aceclidine was "incomparably better", but gave no statistical evaluation.
(2) AQUEOUS OUTFLOW It was this aspect of the effect of direct-acting parasympathomimetic miotics that appeared to be the most intriguing. In the present study, aceclidine was found to have a definite effect in improving the facility of outflow in eyes with open-angle glaucoma. The difference in the mean C-value of cases on pilocarpine and aceclidine was ooI (full trial trial cases difference = o; non-placebo cases difference = o 0o 1). Lieberman and Leopold stated categorically that, so far as their work was concerned, aceclidine had no effect whatsoever on outflow facility (except in their chronic simple glaucoma suspects and secondary glaucoma cases), a unique property in a miotic. They observed a definite pressure-lowering effect, which led them to a most interesting theoretical discussion of how the drug produced this effect (see below). Demailly (I968), in his chronic and acute experiments, found that aceclidine produced a significant improvement in outflow but was no significant difference between the effects of pilocarpine 2 per cent. and aceclidine HCI 2 per cent. on the C-value or on P./C. However, the effect of aceclidine was consistently less powerful. A study, in the acute experiments, of the logarithm of the C-values, usually of a Gaussian distribution in normal subjects, revealed a significantly greater improvement with pilocarpine than with aceclidine. Among the other studies, ttienne and others (I967) found a highly significant improvement of outflow with aceclidine in cases of glaucoma simplex; the mean improvement in the C-value was o-o48. Riegel and Leydhecker (I967) observed an improvement in the C-value with aceclidine from a base line of o* 17 to 02o, rather less than the O*22 obtained with 2 per cent. pilocarpine. Gil del Rio (i 968) found a mean increase of 0o 05 I. Lepri and Tota (i 967) observed an improveinent in C-value of the order of o o3. Brancato and Boschi (I968) observed an "identical" improvement in the C-value on both drugs. Magouritsas and Coliopoulos (in press) and Mazzilli and Mazza (i967) also observed a definite improvement in outflow.
Of all the published studies, therefore, only that of Lieberman and Leopold (1967) reports no improvement in outflow with aceclidine.
Mechanism of the effect of the two drugs (a) It could conceivably be produced by a reduction of aqueous formation. Pilocarpine itself has been demonstrated to have an inhibitory effect on the ciliary process in vitro (Berggren, I965) . This effect has not been studied for aceclidine.
(b) Demailly, comparing the effect of the two drugs, explained the greater tensionlowering effect of aceclidine by the smaller amount of reactive hypersecretion which occurs 5I7 group.bmj.com on July 3, 2017 -Published by http://bjo.bmj.com/ Downloaded from 5John H. Romano after the use of both drugs. That this effect was indeed greater with pilocarpine was suggested by flow-studies, using both the results of tonography, with Goldmann's F = (P0 -P) formula, and suction cup studies.
(c) BArany (I962), experimenting on the monkey Cercopithecus ethiops, demonstrated that the increase in outflow facility produced by pilocarpine could be reversed by atropine in two stages, a fast and a slow. The fast stage lasted approximately as long as the accommodative spasm produced by pilocarpine, and could correspond to a facilitation of outflow produced by a pull of the ciliary muscle on the trabecular meshwork (and possibly on the endothelial cells of Schlemm's canal). The slow phase could correspond to the abolition of a histamine-like action of pilocarpine directly on the endothelial cells or a widening of the transendothelial channels (this latter phenomenon could not be confirmed in later experiments). In some individuals an increase in facility may be mainly due to the ciliary muscle pull, whereas in others it may predominantly correspond to the effect on the endothelium. It is possible that aceclidine lacks the latter effect (it produces intense miosis, so it is probably unlikely to be without effect on the ciliary muscle).
(d) Another explanation could be related to the recent concept of the uveo-scleral flow of aqueous along the interfascicular spaces of the ciliary body directly to the venous circulation (Bill and Barany, I966) . Pilocarpine, possibly by causing ciliary spasm, is thought to close up this alternative pathway for aqueous outflow. The effect of aceclidine has not been studied and it could be weaker than that of pilocarpine.
(3) MIOSIS
In the present study, aceclidine was found to produce slightly more powerful miosis than pilocarpine.
Demailly (I968) obtained the impression that the miosis produced after one hour was greater with aceclidine than with pilocarpine, though the pupillary diameters were not measured. Gil del Rio (I968), using an electronic flash photographic method, noted early miosis with aceclidine, starting 4 minutes after instillation and reaching its maximum between 20 and 8o minutes. ttienne and others (I967) also noted "intense miosis". Rouher (I966) observed miosis after 30 minutes, maximal after go minutes, the pupil then being 47 per cent. of its original diameter. Riegal and Leydhecker (I967) noted a mean pupillary diameter on pilocarpine of I-6 mm. and on aceclidine of I-7 mm. This would appear to be the only study in which the miotic effect of pilocarpine was noted to be stronger than that of aceclidine.
(4) HYPERAEMIA This was more frequent with aceclidine in the present study (Table IV, This occurred in seven cases and was rather more frequent with pilocarpine than with aceclidine (Table IV) . This is in contrast with the observations of ltienne and others (I967), who found that aceclidine produced no sialorrhoea in man as it did in animals.
(9) RHINORRHOEA This occurred in 31 cases, more often with aceclidine than with pilocarpine (Table IV) . 
